Supernus Pharmaceuticals SUPN Debt securities - current
Debt securities - current at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's debt securities - current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Supernus Pharmaceuticals's debt securities - current?
- Supernus Pharmaceuticals (SUPN) reported debt securities - current of $199.37M in Q1 2026.
- How has Supernus Pharmaceuticals's debt securities - current changed year-over-year?
- Supernus Pharmaceuticals's debt securities - current decreased by 42.7% year-over-year, from $347.74M to $199.37M.
- What is the long-term trend for Supernus Pharmaceuticals's debt securities - current?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's debt securities - current has grown at a -21.2% compound annual growth rate (CAGR), from $368.21M to $180.22M.